AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7878164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2304216 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded peer review (authors' and institutions' names removed)
Number of subjects: 127
Study 2304216 — intervention group
Group type: COMPARATOR
Intervention: Non-blinded peer review (authors' and institutions' names included)
Number of subjects: 127
Study 2304216 — intervention group
Group type: EXPERIMENTAL
Intervention: Signing reviews
Number of subjects: 127
Study 2304216 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality association with signing
Number of subjects: 127
Study 41543 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg (short-term study)
Number of subjects: 0
Study 41543 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg (long-term study)
Number of subjects: 0
Study 41543 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29777527 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with premovement cues that allowed for preparatory movement planning
Number of subjects: 0
Study 29777527 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental training to reduce explicit skill knowledge
Number of subjects: 0
Study 28257159 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDIAS 2 BSC
Number of subjects: 182
Study 28257159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study 26452366 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and social worker intervention
Number of subjects: 0
Study 26452366 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and social worker intervention plus financial assistance program
Number of subjects: 0
Study 26452366 — intervention group
Group type: COMPARATOR
Intervention: Usual care while on the transplant waiting list
Number of subjects: 0
Study 22882353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (300,000 IU in six divided doses over 3 months)
Number of subjects: 92
Study 22882353 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular cholecalciferol (300,000 IU as a single injection)
Number of subjects: 92
Study 22882353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 92
Study 21865175 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent PCV given at birth (newborn group)
Number of subjects: 300
Study 21865175 — intervention group
Group type: COMPARATOR
Intervention: 7-valent PCV given at 6, 10, and 14 weeks (EPI group)
Number of subjects: 300
Study 21865175 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent PCV (both groups)
Number of subjects: 300
Study 21865175 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent PCV (newborn group)
Number of subjects: 300
Study 19717691 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling including labelling with COPD plus nortriptyline for smoking cessation
Number of subjects: 205
Study 19717691 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling excluding labelling with COPD plus nortriptyline for smoking cessation
Number of subjects: 205
Study 19717691 — intervention group
Group type: COMPARATOR
Intervention: Care as usual for smoking cessation by the general practitioner without labelling with COPD
Number of subjects: 205
Study 17352284 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive agents (bisphosphonates)
Number of subjects: 0
Study 17352284 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (synthetic 1-34 parathormone)
Number of subjects: 0
Study 17352284 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 17352284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium
Number of subjects: 0
Study 17352284 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin and raloxifene
Number of subjects: 0
Study 15130978 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training in basic nursing and facilitation of personal care techniques
Number of subjects: 300
Study 15130978 — intervention group
Group type: COMPARATOR
Intervention: No caregiver training
Number of subjects: 300
Study 21547704 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 38
Study 21547704 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 38
Study 9757381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 1000
Study 7886763 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for anti-Brugia malayi IgG
Number of subjects: 1561
Study 7886763 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for anti-Brugia malayi IgG4
Number of subjects: 1561
Study 7886763 — intervention group
Group type: COMPARATOR
Intervention: Onchocerca gibsoni circulating antigen (Og4C3)
Number of subjects: 1561
Study 3290156 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 275 mg capsules per headache
Number of subjects: 161
Study 3290156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 31855009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Depression plus Brief Motivational Interviewing (CBT-D + BMI)
Number of subjects: 94
Study 31855009 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Depression (CBT-D)
Number of subjects: 94
Study 29794306 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39439335 (2-50 mg)
Number of subjects: 14
Study 29794306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28805601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (COC) containing 30 μg of EE and 3 mg of drospirenone for 12 consecutive cycles
Number of subjects: 200
Study 26651333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg or 200 μg)/vilanterol 25 μg
Number of subjects: 0
Study 26651333 — intervention group
Group type: COMPARATOR
Intervention: Existing asthma maintenance therapy
Number of subjects: 0
Study 23725677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g)
Number of subjects: 45
Study 23725677 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 45
Study 20948459 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone acetonide anterior injection
Number of subjects: 96
Study 20948459 — intervention group
Group type: EXPERIMENTAL
Intervention: anterior injection followed by laser
Number of subjects: 96
Study 20948459 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide posterior injection
Number of subjects: 96
Study 20948459 — intervention group
Group type: EXPERIMENTAL
Intervention: posterior injection followed by laser
Number of subjects: 96
Study 20948459 — intervention group
Group type: COMPARATOR
Intervention: laser group
Number of subjects: 96
Study 19088352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 210
Study 19088352 — intervention group
Group type: COMPARATOR
Intervention: High-cereal fiber diet
Number of subjects: 210
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient consent before randomisation
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative assent
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusal of relative assent post-randomisation
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: No relatives available for assent
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear documentation on relative assent
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival of patients who did not provide consent prior to randomisation
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective informed consent after survival
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusal of retrospective informed consent
Number of subjects: 498
Study 17019555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not regain mental competency
Number of subjects: 498
Study 14983953 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with PSA (total PSA and free PSA) using Prostatus f/tPSA assay.
Number of subjects: 19946
Study 14983953 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold tPSA of >= 4.0 ng/mL
Number of subjects: 19946
Study 14983953 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold tPSA of >= 3.0 ng/mL combined with f/tPSA threshold of <= 18%
Number of subjects: 19946
Study 14606149 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative reservation of autoblood
Number of subjects: 143
Study 14606149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative reservation of autoblood)
Number of subjects: 143
Study 10217588 — intervention group
Group type: EXPERIMENTAL
Intervention: FluMist (live attenuated cold adapted trivalent intranasal influenza vaccine)
Number of subjects: 100
Study 10217588 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 100
Study 7641902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (group B, n = 50)
Number of subjects: 74
Study 7641902 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (group A, n = 50)
Number of subjects: 74
Study 2491360 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 10 mg every morning
Number of subjects: 270
Study 2491360 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg every morning
Number of subjects: 270
Study 2491360 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 270
Study 2491360 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole groups (both dosages)
Number of subjects: 270
Study 2491360 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole and ranitidine groups
Number of subjects: 270
Study 1095098 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 rads daily five times weekly for four weeks
Number of subjects: 30
Study 1095098 — intervention group
Group type: COMPARATOR
Intervention: 400 rads twice weekly for four weeks
Number of subjects: 30
Study 28211107 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate (95%) applied by healthcare professional (clinical group)
Number of subjects: 113
Study 28211107 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate (95%) self-applied (home group)
Number of subjects: 113
Study 28211107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (clinical and home application)
Number of subjects: 113
Study 25818492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 78
Study 25818492 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride with adrenaline
Number of subjects: 78
Study 24089693 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week free nicotine replacement therapy (NRT) with behavioural counselling
Number of subjects: 562
Study 24089693 — intervention group
Group type: COMPARATOR
Intervention: 2-week free nicotine replacement therapy (NRT) with behavioural counselling
Number of subjects: 562
Study 21843494 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic drainage
Number of subjects: 39
Study 21843494 — intervention group
Group type: COMPARATOR
Intervention: Surgical drainage (operative pancreaticojejunostomy)
Number of subjects: 39
Study 19289640 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR of 2.5 to 3.0)
Number of subjects: 1587
Study 19289640 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 1587
Study 19289640 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (162 mg once daily)
Number of subjects: 1587
Study 17784893 — intervention group
Group type: EXPERIMENTAL
Intervention: TND Network (peer-led interactive version of TND)
Number of subjects: 541
Study 17784893 — intervention group
Group type: COMPARATOR
Intervention: Control classes (no intervention)
Number of subjects: 541
Study 17784893 — intervention group
Group type: EXPERIMENTAL
Intervention: Towards No Drug Abuse (TND)
Number of subjects: 541
Study 15271109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community nurse (CN)‐supported discharge program
Number of subjects: 157
Study 15271109 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge care)
Number of subjects: 157
Study 12171689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement containing glucosamine, amino acids, minerals, and antioxidants
Number of subjects: 53
Study 12171689 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 individuals who did not take the supplement)
Number of subjects: 53
Study 9764631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 88
Study 9764631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 7919326 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose (500 mL of plasma)
Number of subjects: 220
Study 7919326 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose (250 mL of plasma diluted in 250 mL of 5% human serum albumin)
Number of subjects: 220
Study 7919326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL of 5% human serum albumin)
Number of subjects: 220
Study 3277494 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists in combination with diuretics
Number of subjects: 0
Study 3277494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose diuretic and calcium blocker
Number of subjects: 0
Study 31914324 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/day)
Number of subjects: 76
Study 31914324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 30772862 — intervention group
Group type: EXPERIMENTAL
Intervention: LuCApp in addition to standard care
Number of subjects: 120
Study 30772862 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 27307056 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS program
Number of subjects: 635
Study 27307056 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Cuídate! program
Number of subjects: 635
Study 27307056 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 635
Study 25931244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (15 g every 8 hours for 7 days)
Number of subjects: 800
Study 25931244 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (750 mg once daily for 7 days)
Number of subjects: 800
Study 23412015 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 563
Study 23412015 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 563
Study 21042870 — intervention group
Group type: EXPERIMENTAL
Intervention: S.S.GRIN‐HFA (n = 27)
Number of subjects: 55
Study 21042870 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional S.S.GRIN intervention; n = 28)
Number of subjects: 55
Study 19255022 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 103
Study 19255022 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 103
Study 19255022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 16728219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel PCI
Number of subjects: 4744
Study 16728219 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel PCI
Number of subjects: 4744
Study 16728219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel PCI with acute coronary syndrome
Number of subjects: 4744
Study 16728219 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel PCI with acute coronary syndrome
Number of subjects: 4744
Study 14982764 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 17
Study 14982764 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 17
Study 11917970 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 9234030 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of beans twice or more per week
Number of subjects: 1010
Study 9234030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dietary intake
Number of subjects: 1010
Study 7955823 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of lomefloxacin
Number of subjects: 0
Study 7955823 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of lomefloxacin
Number of subjects: 0
Study 3117156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 0
Study 3117156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29921613 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 103
Study 29921613 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 103
Study 28294430 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXEQ2W)
Number of subjects: 2570
Study 28294430 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXEQ4W)
Number of subjects: 2570
Study 28294430 — intervention group
Group type: COMPARATOR
Intervention: 50 mg etanercept (ETN) twice weekly
Number of subjects: 2570
Study 28294430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2570
Study 28294430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both schedules)
Number of subjects: 2570
Study 26703684 — intervention group
Group type: EXPERIMENTAL
Intervention: ASUMA intervention
Number of subjects: 135
Study 26703684 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 24660272 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP combined with 1.7% hydrogen peroxide gel (Perio Gel) using custom trays
Number of subjects: 30
Study 24660272 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study 21980827 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/day)
Number of subjects: 29
Study 21980827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17555327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g of DNJ-enriched powder (12 mg of DNJ)
Number of subjects: 0
Study 17555327 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of DNJ-enriched powder (18 mg of DNJ)
Number of subjects: 0
Study 17555327 — intervention group
Group type: COMPARATOR
Intervention: 0 g of DNJ-enriched powder (0 mg of DNJ)
Number of subjects: 0
Study 15321435 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 0 micrograms (control)
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 5 micrograms
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 10 micrograms
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 15 micrograms
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 micrograms
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: All fentanyl groups (15, 20, 25 micrograms)
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: All fentanyl groups (0, 5, 10 micrograms)
Number of subjects: 0
Study 15321435 — intervention group
Group type: EXPERIMENTAL
Intervention: All fentanyl groups
Number of subjects: 0
Study 11136787 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC treatment (macrolide therapy)
Number of subjects: 0
Study 11136787 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV‐1-infected persons without MAC bacteremia)
Number of subjects: 0
Study 9638782 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation program (clinic tour, general information, Q&A session with oncology counselor)
Number of subjects: 150
Study 9638782 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 150
Study 8209276 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy (arm B)
Number of subjects: 85
Study 8209276 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 85
Study 2563311 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (mean dose, 5 mg per day)
Number of subjects: 23
Study 2563311 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (mean dose, 133 mg per day)
Number of subjects: 23
Study 31544432 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirschner wire-fixation-cortical bone technique
Number of subjects: 40
Study 31544432 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study 29787743 — intervention group
Group type: EXPERIMENTAL
Intervention: Scvo2 < 70% at 6 hours in subjects with initial Scvo2 < 70%
Number of subjects: 1475
Study 29787743 — intervention group
Group type: EXPERIMENTAL
Intervention: Scvo2 < 70% at 6 hours in subjects with initial Scvo2 ≥ 70%
Number of subjects: 1475
Study 26838150 — intervention group
Group type: EXPERIMENTAL
Intervention: Live display of the dental operating microscope (DOM)
Number of subjects: 90
Study 26838150 — intervention group
Group type: COMPARATOR
Intervention: Tell‐Show‐Do (TSD) technique without DOM
Number of subjects: 90
Study 24285635 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet + Pedometer (GB + P)
Number of subjects: 31
Study 24285635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer + Booklet (GP + B)
Number of subjects: 31
Study 23065000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 205
Study 23065000 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg
Number of subjects: 205
Study 19967563 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (900 mg per day for 6 months)
Number of subjects: 25